Loading...
XNAS
GILD
Market cap139bUSD
Apr 02, Last price  
111.89USD
1D
0.55%
1Q
21.78%
Jan 2017
56.25%
Name

Gilead Sciences Inc

Chart & Performance

D1W1MN
No data to show
P/E
290.30
P/S
4.85
EPS
0.39
Div Yield, %
2.06%
Shrs. gr., 5y
-0.35%
Rev. gr., 5y
5.08%
Revenues
28.75b
+6.04%
2,028,400,0003,026,139,0004,230,045,0005,335,750,0007,011,383,0007,949,420,0008,385,385,0009,702,517,00011,201,688,00024,890,000,00032,639,000,00030,390,000,00026,107,000,00022,127,000,00022,449,000,00024,689,000,00027,305,000,00027,281,000,00027,116,000,00028,754,000,000
Net income
480m
-91.53%
813,914,000-1,189,957,0001,615,298,0002,011,154,0002,635,755,0002,901,257,0002,803,637,0002,591,566,0003,074,808,00012,101,000,00018,108,000,00013,501,000,0004,628,000,0005,455,000,0005,386,000,00089,000,0006,225,000,0004,592,000,0005,665,000,000480,000,000
CFO
10.83b
+35.25%
715,080,0001,218,059,0001,765,398,0002,204,659,0003,080,054,0002,833,913,0003,639,010,0003,194,716,0003,104,988,00012,818,000,00020,329,000,00016,669,000,00011,898,000,0008,400,000,0009,144,000,0008,168,000,00011,384,000,0009,072,000,0008,006,000,00010,828,000,000
Dividend
Sep 13, 20240.77 USD/sh
Earnings
Apr 23, 2025

Profile

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
URL
https://www.gilead.com/
IPO date
Jan 22, 1992
Employees
17,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
28,754,000
6.04%
27,116,000
-0.60%
27,281,000
-0.09%
Cost of revenue
12,158,000
19,511,000
16,307,000
Unusual Expense (Income)
NOPBT
16,596,000
7,605,000
10,974,000
NOPBT Margin
57.72%
28.05%
40.23%
Operating Taxes
211,000
1,247,000
1,248,000
Tax Rate
1.27%
16.40%
11.37%
NOPAT
16,385,000
6,358,000
9,726,000
Net income
480,000
-91.53%
5,665,000
23.37%
4,592,000
-26.23%
Dividends
(3,918,000)
(3,809,000)
(3,709,000)
Dividend yield
3.38%
3.74%
3.42%
Proceeds from repurchase of equity
(728,000)
(768,000)
(1,087,000)
BB yield
0.63%
0.75%
1.00%
Debt
Debt current
1,815,000
1,798,000
2,273,000
Long-term debt
2,590,000
24,469,000
24,136,000
Deferred revenue
Other long-term liabilities
25,726,000
3,319,000
5,095,000
Net debt
(7,163,000)
17,840,000
17,534,000
Cash flow
Cash from operating activities
10,828,000
8,006,000
9,072,000
CAPEX
(523,000)
(585,000)
(728,000)
Cash from investing activities
(3,449,000)
(2,265,000)
(2,466,000)
Cash from financing activities
(3,433,000)
(5,125,000)
(6,469,000)
FCF
16,835,000
6,376,000
8,965,000
Balance
Cash
11,568,000
7,264,000
7,630,000
Long term investments
1,163,000
1,245,000
Excess cash
10,130,300
7,071,200
7,510,950
Stockholders' equity
11,546,000
16,249,000
15,659,000
Invested Capital
37,951,700
43,983,800
43,064,050
ROIC
39.99%
14.61%
22.04%
ROCE
34.00%
14.45%
20.61%
EV
Common stock shares outstanding
1,255,000
1,258,000
1,262,000
Price
92.37
14.02%
81.01
-5.64%
85.85
18.23%
Market cap
115,924,350
13.75%
101,910,580
-5.94%
108,342,700
18.23%
EV
108,677,350
119,666,580
125,845,700
EBITDA
19,363,000
10,298,000
13,077,000
EV/EBITDA
5.61
11.62
9.62
Interest
977,000
944,000
935,000
Interest/NOPBT
5.89%
12.41%
8.52%